Straits Times Index
3,306.02 +6.02 (+0.18%) S&P 500
5,464.62 -8.55 (-0.16%) Dow
39,150.33 +15.53 (+0.04%) Nasdaq
17,689.36 -32.24 (-0.18%) Bitcoin USD
64,098.62 -124.05 (-0.19%) CMC Crypto 200
1,321.99 -38.34 (-2.82%)
Sandoz Group AG (SDZNY)
| Previous close | 37.10 |
| Open | 36.67 |
| Bid | 36.18 x 40000 |
| Ask | 37.00 x 40000 |
| Day's range | 36.67 - 36.91 |
| 52-week range | 25.71 - 37.12 |
| Volume | |
| Avg. volume | 106,759 |
| Market cap | 15.783B |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | 203.94 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 0.50 (1.35%) |
| Ex-dividend date | 03 May 2024 |
| 1y target est | N/A |
- GlobeNewswire
Improving access for patients: launch of Lisdexamfetamine further broadens Sandoz Canada portfolio
Michel Robidoux Michel Robidoux PrSandoz® Lisdexamfetamine, one of first generic equivalents of Vyvanse*, available on Canadian marketApproved for all indications of reference medicine: Attention Deficit Hyperactivity Disorder and Binge Eating Disorder in adultsPrSandoz® Amoxicillin, PrSandoz® Desvenlafaxine and PrSandoz® Riociguat also joined Sandoz Canada’s generics portfolio this spring BOUCHERVILLE, Quebec, June 05, 2024 (GLOBE NEWSWIRE) -- Sandoz Canada announced today the launch of PrSando
- GlobeNewswire
Sandoz receives European Commission approval for Wyost® and Jubbonti®, the first and only biosimilars of denosumab in Europe
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Wyost® (denosumab) and Jubbonti® (denosumab) approved by EC for all indications of denosumab reference medicines Xgeva® and Prolia®EC approval based on robust development program confirming that biosimilar matches reference medicine in terms of safety, efficacy and qualityApproved for treatment of cancer-related bone disease and osteoporosis respectively Basel, May 22, 2024 – Sandoz, the global leader in gener
- GlobeNewswire
Sandoz reports first quarter 2024 sales
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Strong first quarter performance, with net sales [1] of USD 2.5 billion, up 6% in constant currencies (up 5% in USD)Biosimilar business growing 21% in constant currencies All regions contributing to growthAcquisition of CIMERLI® (ranibizumab-eqrn) completed in March 2024 Basel, May 7, 2024 – Sandoz (SIX:SDZ/OTCQX:SDZNY), the global leader in generic and biosimilar medicines, today announced net sales for the f
